drugset / Trial / NCT02644252

Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer

NCT02644252

Phase 3 Terminated 79 enrolled Vejle Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

There is a need for improving the effect of first-line chemotherapy for lung cancer patients, preferably by using an approach with none or very few side effects. In this trial the investigators incorporate δ-tocotrienol/placebo as a nutritional supplement on top of standard chemotherapy for patients with advanced non-small cell lung cancer.

Timeline

Start
2016-01
Primary completion
2019-05-09
Completion
2021-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocotrienol Small molecule 300 mg
Background Carboplatin Small molecule
Background Cisplatin Other / unclassified 75 mg/m2
Background Vinorelbine Small molecule 25 mg/m2
Background Vinorelbine Small molecule 30 mg/m2
Background Vinorelbine Small molecule 50 mg/m2
Background Vinorelbine Small molecule 60 mg/m2

Indications